Therapy Areas: Respiratory
Regeneron Pharmaceuticals reports Q1 2018 financial results
4 May 2018 -

Regeneron Pharmaceuticals Inc, a US-based biotechnology company, yesterday reported its financial results for the first quarter of fiscal 2018.

The company announced that Net product sales were USD988m in the first quarter of 2018, compared to USD858m in the first quarter of 2017. Total revenues, which include product revenues, increased by 15% to USD1.511bn in the first quarter of 2018, compared to USD1.319bn in the first quarter of 2017. Total revenues include Sanofi and Bayer collaboration revenues of USD437m in the first quarter of 2018, compared to USD404m in the first quarter of 2017.

GAAP R&D expenses were USD499m in the first quarter of 2018, compared to USD507m in the first quarter of 2017. The lower R&D expenses in the first quarter of 2018 were principally due to a decrease in clinical manufacturing costs and a decrease in dupilumab development costs.

GAAP net income was USD478m, or USD4.44 per basic share and USD4.16 per diluted share, in the first quarter of 2018, compared to GAAP net income of USD249m, or USD2.36 per basic share and USD2.16 per diluted share, in the first quarter of 2017. Non-GAAP net income was USD537m, or USD4.99 per basic share and USD4.67 per diluted share, in the first quarter of 2018, compared to non-GAAP net income of USD337m, or USD3.19 per basic share and USD2.92 per diluted share, in the first quarter of 2017.

Leonard S Schleifer, MD, PhD, president and chief executive officer of Regeneron, commented, 'Regeneron's commercial business continues to advance with positive sales growth for EYLEA and strong underlying demand for Dupixent. This year, we have reported positive Phase 3 results for Praluent in cardiovascular risk reduction and for EYLEA in diabetic retinopathy - and look forward to continued progress with Dupixent, including a US regulatory decision in uncontrolled asthma and Phase 3 results in both adolescents with atopic dermatitis and adults with nasal polyps. Our immuno-oncology portfolio is advancing rapidly, with a potential first approval for cemiplimab in advanced cutaneous squamous cell carcinoma, and a broad pivotal program in lung cancer.'

Login
Username:

Password:


Related Headlines